Regarding the safety of subretinal application, a clinical study reported that no patients presented geographic atrophy or signs of retinal degeneration after subretinal anti-VEGF injection and the final visual improvement in most patients proves a tolerance of highly concentrated anti-VEGF agents in the subretinal space [6]. The gene discussed is VEGFA; the disease is retinal degeneration.